Cargando…

Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer

SIMPLE SUMMARY: Testing for a homologous recombination deficiency (HRD) in primary high-grade ovarian cancer is crucial for recommending the appropriate therapy. Patients with a BRCA germline mutation are defined as harboring an HRD deficiency. However, there is a group of approximately 20% of patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heitz, Florian, Ataseven, Beyhan, Staniczok, Claudia, Denkert, Carsten, Rhiem, Kerstin, Hahnen, Eric, Heikaus, Sebastian, Moubarak, Malak, Welz, Julia, Dagres, Timoleon, Vrentas, Vasilios, Bommert, Mareike, Schneider, Stephanie, Concin, Nicole, Harter, Philipp
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913091/ https://www.ncbi.nlm.nih.gov/pubmed/36765776 http://dx.doi.org/10.3390/cancers15030818

Ejemplares similares

Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients
por: Imterat, Majdi, et al.
Publicado: (2023)

Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience
por: Moubarak, Malak, et al.
Publicado: (2022)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Pathogenic germline variants in SMARCA4 and further cancer predisposition genes in early onset ovarian cancer
por: Herold, Natalie, et al.
Publicado: (2023)

Response to the letter of Fagotti et al. regarding the manuscript: “Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery”
por: Heitz, Florian, et al.
Publicado: (2016)

Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer
por: Heitz, Florian, et al.
Publicado: (2022)

Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer – Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?
por: Ataseven, Beyhan, et al.
Publicado: (2020)

Dataset on patients with Recurrent Borderline Ovarian Tumors and Table with Review of Literature on Fertility and Oncologic Outcomes of patients with Borderline Ovarian Tumors
por: Plett, Helmut, et al.
Publicado: (2020)

HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?
por: Kekeeva, Tatiana, et al.
Publicado: (2023)

Satisfaction and Quality of Life of Healthy and Unilateral Diseased BRCA1/2 Pathogenic Variant Carriers after Risk-Reducing Mastectomy and Reconstruction Using the BREAST-Q Questionnaire
por: Herold, Natalie, et al.
Publicado: (2022)

Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Heitz, Florian, et al.
Publicado: (2019)

Implementing HRD technology /
Publicado: (1999)

Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring
por: Braicu, Elena Ioana, et al.
Publicado: (2021)

Cryo-EM structure of the protein-conducting ERAD channel Hrd1 in complex with Hrd3
por: Schoebel, Stefan, et al.
Publicado: (2017)

Endoplasmic Reticulum Degradation Requires Lumen to Cytosol Signaling: Transmembrane Control of Hrd1p by Hrd3p
por: Gardner, Richard G., et al.
Publicado: (2000)

A Hrd way for MHC-II expression
por: Melo-Cardenas, Johanna, et al.
Publicado: (2015)

Homologous Recombination Deficiency (HRD) in Cutaneous Oncology
por: Akinjiyan, Favour A., et al.
Publicado: (2023)

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
por: Kim, Hana, et al.
Publicado: (2021)

The role of Hrd1 in ultraviolet (UV) radiation induced photoaging
por: Jin, Yi, et al.
Publicado: (2020)

Increased HRD score in cisplatin resistant penile cancer cells
por: Winkelmann, Ria, et al.
Publicado: (2022)

Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice
por: Bruzas, Simona, et al.
Publicado: (2021)

Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial
por: Gerber, Bernd, et al.
Publicado: (2022)

Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature
por: Herold, Natalie, et al.
Publicado: (2018)

Hurconomics for Talent Management: The Creation of a Business-driven HRD Missionary
por: Rao, T
Publicado: (2011)

Herp coordinates compartmentalization and recruitment of HRD1 and misfolded proteins for ERAD
por: Leitman, Julia, et al.
Publicado: (2014)

Proteomic characterization of endogenous substrates of mammalian ubiquitin ligase Hrd1
por: Ye, Yilin, et al.
Publicado: (2018)

Putative Interaction Proteins of the Ubiquitin Ligase Hrd1 in Magnaporthe oryzae
por: Jiang, Haolang, et al.
Publicado: (2018)

DNA mapping and kinetic modeling of the HrdB regulon in Streptomyces coelicolor
por: Šmídová, Klára, et al.
Publicado: (2019)

Cycles of autoubiquitination and deubiquitination regulate the ERAD ubiquitin ligase Hrd1
por: Peterson, Brian G, et al.
Publicado: (2019)

Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
por: Magliacane, Gilda, et al.
Publicado: (2022)

HRD-related morphology discovery in breast cancer by controlling for confounding factors
por: Schirris, Yoni, et al.
Publicado: (2022)

Modularity of the Hrd1 ERAD complex underlies its diverse client range
por: Kanehara, Kazue, et al.
Publicado: (2010)

Proteasomal Degradation of Proinsulin Requires Derlin-2, HRD1 and p97
por: Hoelen, Hanneke, et al.
Publicado: (2015)

USP19-Mediated Deubiquitination Facilitates the Stabilization of HRD1 Ubiquitin Ligase
por: Harada, Kumi, et al.
Publicado: (2016)

Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)
por: Menzel, Michael, et al.
Publicado: (2023)

A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer
por: Chen, Kuei-Ting, et al.
Publicado: (2023)

In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay
por: Fumagalli, Caterina, et al.
Publicado: (2022)

BRCA2 Mutations and Triple-Negative Breast Cancer
por: Meyer, Peter, et al.
Publicado: (2012)

Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC)
por: Fotopoulou, Christina, et al.
Publicado: (2021)

Aberrant substrate engagement of the ER translocon triggers degradation by the Hrd1 ubiquitin ligase
por: Rubenstein, Eric M., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_mhjuo4nnngdti58irb07gb7dnl